Summary of Recognized Revenue |
The Company has recognized revenue as follows:
|
|
Three Months Ended
September 30,
|
|
|
Nine Months Ended
September 30,
|
|
|
|
2018
|
|
|
2017
|
|
|
2018
|
|
|
2017
|
|
|
|
(in thousands)
|
|
|
(in thousands)
|
|
Collaboration revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Celgene Corporation (“Celgene”)—related party:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of up-front payment
|
|
$
|
1,655
|
|
|
$
|
2,642
|
|
|
$
|
4,912
|
|
|
$
|
16,355
|
|
Research and development services
|
|
|
5
|
|
|
|
–
|
|
|
|
103
|
|
|
|
–
|
|
Milestones and contingent payments
|
|
|
–
|
|
|
|
13,112
|
|
|
|
|
|
|
|
25,937
|
|
Total
|
|
|
1,660
|
|
|
|
15,754
|
|
|
|
5,015
|
|
|
|
42,292
|
|
Merck Sharp & Dohme Corporation (“Merck”)—related party:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of up-front payment
|
|
|
2,818
|
|
|
|
–
|
|
|
|
2,818
|
|
|
|
–
|
|
Research and development services
|
|
|
696
|
|
|
|
–
|
|
|
|
696
|
|
|
|
–
|
|
Total
|
|
|
3,514
|
|
|
|
–
|
|
|
|
3,514
|
|
|
|
–
|
|
Merck KGaA, Darmstadt, Germany (operating in the United
States and Canada under the name “EMD Serono”):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of up-front payment
|
|
|
1,038
|
|
|
|
1,030
|
|
|
|
3,104
|
|
|
|
3,090
|
|
Research and development services
|
|
|
712
|
|
|
|
715
|
|
|
|
2,322
|
|
|
|
2,319
|
|
Total
|
|
|
1,750
|
|
|
|
1,745
|
|
|
|
5,426
|
|
|
|
5,409
|
|
Total collaboration revenue
|
|
$
|
6,924
|
|
|
$
|
17,499
|
|
|
$
|
13,955
|
|
|
$
|
47,701
|
|
Other revenue—related parties:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Celgene Corporation:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Development and manufacturing services and clinical
product supply
|
|
$
|
330
|
|
|
$
|
–
|
|
|
$
|
3,894
|
|
|
$
|
–
|
|
SutroVax:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supply and other
|
|
|
582
|
|
|
|
–
|
|
|
|
1,484
|
|
|
|
–
|
|
Total other revenue—related parties
|
|
$
|
912
|
|
|
$
|
–
|
|
|
$
|
5,378
|
|
|
$
|
–
|
|
Total revenue
|
|
$
|
7,836
|
|
|
$
|
17,499
|
|
|
$
|
19,333
|
|
|
$
|
47,701
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|